# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
bluebird bio, Inc. (NASDAQ:BLUE) today announced that it received a notice (the "notice") on April 24, 2024 from The Na...
- SEC Filing
RBC Capital analyst Luca Issi reiterates bluebird bio (NASDAQ:BLUE) with a Sector Perform and maintains $6 price target.
Wells Fargo analyst Yanan Zhu maintains bluebird bio (NASDAQ:BLUE) with a Equal-Weight and lowers the price target from $4 t...